Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 517 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sepsis Clear all

Conditions: Artifical Inteligence, Cardiology, Breast Cancer, Sepsis
Interventions: AI-PERSONALIZED CLINICAL DECISION SUPPORT; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 300,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sepsis, Severe Infection
Interventions: CBC-Diff Monocyte volume width distribution (MDW); Diagnostic Test
Lead sponsor: Beckman Coulter, Inc.; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Hackensack, New Jersey • Columbus, Ohio • Pittsburgh, Pennsylvania

Conditions: Sepsis, Diagnosis, Emergencies
Interventions: Pediatric Sepsis Diagnostic Toolkit; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 1 Month and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions: Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more

Conditions: Sepsis
Interventions: Multimodal therapeutic warming w/ esophageal d/c, Multimodal therapeutic warming w/ conductive d/c; Other
Lead sponsor: Nicholas M Mohr; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Iowa City, Iowa • Minneapolis, Minnesota • St Louis, Missouri

Conditions: Healthy
Interventions: LabClasp; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sepsis, Respiratory Failure, Agitation
Interventions: Propofol, Dexmedetomidine, Fentanyl; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Enterococcal Bacteremia
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 8
States / cities: Miami, Florida • Detroit, Michigan • Jackson, Mississippi + 4 more

Conditions: Burn Wounds
Interventions: SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel, SILVADENE Cream 1% (silver sulfadiazine); Device · Drug
Lead sponsor: Synedgen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Acute Respiratory Distress Syndrome, Sepsis
Interventions: Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%), Inhaled Medical air; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Boston, Massachusetts • St Louis, Missouri • Brooklyn, New York + 2 more

Conditions: Severe Sepsis, Coagulopathy
Interventions: ART-123, Placebo; Drug
Lead sponsor: Asahi Kasei Pharma America Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 816 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 22
States / cities: Mobile, Alabama • Phoenix, Arizona • Atlanta, Georgia + 17 more

Conditions: Sepsis, Alcoholism
Interventions: Observational study; no interventions; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Neonatal Sepsis
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 3 Days and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Charlottesville, Virginia

Conditions: Severe Sepsis, Septic Shock
Interventions: Not listed
Lead sponsor: Brahms AG; Industry
Eligibility: 18 Years and older
Enrollment: 858 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Sacramento, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Catheterization
Interventions: 3.15% chlorhexidine as daily antiseptic on needleless access port; Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 6 Months
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Respiratory Tract Infections
Interventions: MeMed BV® biomarker test, Usual care; Diagnostic Test
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sepsis
Interventions: ECHO, Blood Draw; Procedure
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Boston, Massachusetts • The Bronx, New York • Winston-Salem, North Carolina + 4 more

Conditions: Bacterial Infections
Interventions: Central Venous Catheter; Device
Lead sponsor: Angiotech Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 21
States / cities: Birmingham, Alabama • Orange, California • San Diego, California + 17 more

Conditions: Infection
Interventions: Antimicrobial Solution; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sepsis
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: Jonathan Sevransky; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Septic Shock
Interventions: selepressin, placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 868 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 17
States / cities: Colorado Springs, Colorado • Idaho Falls, Idaho • Chicago, Illinois + 13 more

Conditions: Sepsis
Interventions: Intravenous GR270773- Phospholipid Emulsion, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 132
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 110 more

Conditions: Septic Shock
Interventions: L-Carnitine, Normal Saline; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Jackson, Mississippi • Charlotte, North Carolina

Conditions: Sepsis, Non-Infectious Systemic Inflammatory Response Syndrome
Interventions: SeptiCyte (various); Diagnostic Test
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Month to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Seattle, Washington

Search by objective public record fields.

Safe and Explainable AI

Evaluation of Monocyte Volume Distribution Width (MDW) for Early Detection of Sepsis

The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

Working Toward the Advancement of Recovery Using Modulated Therapeutic Hyperthermia (WARMTH) in Sepsis - Pilot

Estimating Blood [Lactate] Non-Invasively

Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure

VENOUS: A Translational Study of Enterococcal Bacteremia

SWC for Treatment of Superficial Partial-Thickness Burns

Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)

Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

Relationship Between Alcohol Use Disorders and Cortisol Levels in Patients With Sepsis

Improved Detection of Neonatal Sepsis Using a Targeted Biomarker Assay

Procalcitonin Monitoring Sepsis Study

Study of Chlorhexidine as the Hub Antiseptic to Prevent Catheter Related Infections in Newborn Infants

An Adjunct Test Distinguishing Bacterial From Viral Etiology Improves Resource Utilization and Efficiency in the ED.

Study of Treatment's Echocardiographic Mechanisms

Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization

Antimicrobial Catheter Lock Solution for the Treatment of Central Line Associated Bloodstream Infection (CLABSI)

Alirocumab in Patients with Sepsis

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults

L-Carnitine Administration in Early Sepsis

Gene Expression Objective Definition of Early Sepsis In Children